Bank Julius Baer & Co. Ltd Zurich bought a new position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 365,833 shares of the company's stock, valued at approximately $8,126,000. Bank Julius Baer & Co. Ltd Zurich owned approximately 0.18% of Cellebrite DI at the end of the most recent quarter.
Several other hedge funds have also modified their holdings of the stock. JPMorgan Chase & Co. boosted its stake in shares of Cellebrite DI by 21.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 427,655 shares of the company's stock valued at $7,202,000 after purchasing an additional 75,092 shares during the last quarter. Telemark Asset Management LLC bought a new position in Cellebrite DI in the third quarter valued at approximately $6,736,000. Two Sigma Advisers LP boosted its stake in Cellebrite DI by 9.8% in the third quarter. Two Sigma Advisers LP now owns 1,341,100 shares of the company's stock valued at $22,584,000 after acquiring an additional 120,000 shares during the last quarter. Harbor Capital Advisors Inc. grew its holdings in Cellebrite DI by 65.4% during the 4th quarter. Harbor Capital Advisors Inc. now owns 157,671 shares of the company's stock worth $3,473,000 after acquiring an additional 62,320 shares during the period. Finally, State Street Corp raised its position in shares of Cellebrite DI by 7.3% during the 3rd quarter. State Street Corp now owns 443,700 shares of the company's stock valued at $7,472,000 after acquiring an additional 30,052 shares during the last quarter. 45.88% of the stock is owned by institutional investors.
Cellebrite DI Stock Down 1.9 %
Shares of CLBT traded down $0.34 on Thursday, hitting $17.28. The company's stock had a trading volume of 976,648 shares, compared to its average volume of 1,120,083. The firm's fifty day moving average price is $21.58 and its 200-day moving average price is $19.70. Cellebrite DI Ltd. has a fifty-two week low of $10.25 and a fifty-two week high of $26.30. The firm has a market capitalization of $3.56 billion, a price-to-earnings ratio of -12.43, a P/E/G ratio of 4.27 and a beta of 1.53.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. As a group, equities analysts predict that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
CLBT has been the subject of a number of analyst reports. JPMorgan Chase & Co. lifted their price objective on Cellebrite DI from $24.00 to $28.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 11th. Lake Street Capital boosted their target price on Cellebrite DI from $17.00 to $26.00 and gave the stock a "buy" rating in a research report on Friday, February 14th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $28.00 price target on shares of Cellebrite DI in a research report on Monday. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, Cellebrite DI presently has an average rating of "Buy" and a consensus price target of $23.43.
Check Out Our Latest Report on CLBT
Cellebrite DI Profile
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Featured Articles
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
